These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

382 related items for PubMed ID: 16397038

  • 1. Prognostic and predictive effects of immunohistochemical factors in high-risk primary breast cancer patients.
    Kröger N, Milde-Langosch K, Riethdorf S, Schmoor C, Schumacher M, Zander AR, Löning T.
    Clin Cancer Res; 2006 Jan 01; 12(1):159-68. PubMed ID: 16397038
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Stem cell dose and tumorbiologic parameters as prognostic markers for patients with metastatic breast cancer undergoing high-dose chemotherapy with autologous blood stem cell support.
    Hensel M, Schneeweiss A, Sinn HP, Egerer G, Kornacker M, Solomayer E, Haas R, Bastert G, Ho AD.
    Stem Cells; 2002 Jan 01; 20(1):32-40. PubMed ID: 11796920
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Male breast carcinoma: correlation of ER, PR, Ki-67, Her2-Neu, and p53 with treatment and survival, a study of 65 cases.
    Wang-Rodriguez J, Cross K, Gallagher S, Djahanban M, Armstrong JM, Wiedner N, Shapiro DH.
    Mod Pathol; 2002 Aug 01; 15(8):853-61. PubMed ID: 12181271
    [Abstract] [Full Text] [Related]

  • 7. Can expression of apoptosis genes, bcl-2 and bax, predict survival and responsiveness to chemotherapy in node-negative breast cancer patients?
    Kymionis GD, Dimitrakakis CE, Konstadoulakis MM, Arzimanoglou I, Leandros E, Chalkiadakis G, Keramopoulos A, Michalas S.
    J Surg Res; 2001 Aug 01; 99(2):161-8. PubMed ID: 11469882
    [Abstract] [Full Text] [Related]

  • 8. Decreased immunoreactivity for p27 protein in patients with early-stage breast carcinoma is correlated with HER-2/neu overexpression and with benefit from one course of perioperative chemotherapy in patients with negative lymph node status: results from International Breast Cancer Study Group Trial V.
    Spataro VJ, Litman H, Viale G, Maffini F, Masullo M, Golouh R, Martinez-Tello FJ, Grigolato P, Shilkin KB, Gusterson BA, Castiglione-Gertsch M, Price K, Lindtner J, Cortés-Funes H, Simoncini E, Byrne MJ, Collins J, Gelber RD, Coates AS, Goldhirsch A, International Breast Cancer Study Group.
    Cancer; 2003 Apr 01; 97(7):1591-600. PubMed ID: 12655514
    [Abstract] [Full Text] [Related]

  • 9. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
    Martín M, Rodríguez-Lescure A, Ruiz A, Alba E, Calvo L, Ruiz-Borrego M, Munárriz B, Rodríguez CA, Crespo C, de Alava E, López García-Asenjo JA, Guitián MD, Almenar S, González-Palacios JF, Vera F, Palacios J, Ramos M, Gracia Marco JM, Lluch A, Alvarez I, Seguí MA, Mayordomo JI, Antón A, Baena JM, Plazaola A, Modolell A, Pelegrí A, Mel JR, Aranda E, Adrover E, Alvarez JV, García Puche JL, Sánchez-Rovira P, Gonzalez S, López-Vega JM, GEICAM 9906 Study Investigators.
    J Natl Cancer Inst; 2008 Jun 04; 100(11):805-14. PubMed ID: 18505968
    [Abstract] [Full Text] [Related]

  • 10. Coexistence of HER2 over-expression and p53 protein accumulation is a strong prognostic molecular marker in breast cancer.
    Yamashita H, Nishio M, Toyama T, Sugiura H, Zhang Z, Kobayashi S, Iwase H.
    Breast Cancer Res; 2004 Jun 04; 6(1):R24-30. PubMed ID: 14680497
    [Abstract] [Full Text] [Related]

  • 11. Multivariate analysis of bcl-2, apoptosis, P53 and HER-2/neu in breast cancer: a short-term follow-up.
    el-Ahmady O, el-Salahy E, Mahmoud M, Wahab MA, Eissa S, Khalifa A.
    Anticancer Res; 2002 Jun 04; 22(4):2493-9. PubMed ID: 12174951
    [Abstract] [Full Text] [Related]

  • 12. Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401.
    Scandinavian Breast Group Trial 9401Laboratory of Cancer Biology, Institute of Medical Technology, and Department of Oncology, Tampere University and Tampere University Hospital, Tampere, Finland., Tanner M, Isola J, Wiklund T, Erikstein B, Kellokumpu-Lehtinen P, Malmström P, Wilking N, Nilsson J, Bergh J.
    J Clin Oncol; 2006 Jun 01; 24(16):2428-36. PubMed ID: 16682728
    [Abstract] [Full Text] [Related]

  • 13. Prognostic value of Bcl-2 in invasive breast cancer receiving chemotherapy and endocrine therapy.
    Yang Q, Sakurai T, Yoshimura G, Suzuma T, Umemura T, Nakamura M, Nakamura Y, Mori I, Kakudo K.
    Oncol Rep; 2003 Jun 01; 10(1):121-5. PubMed ID: 12469156
    [Abstract] [Full Text] [Related]

  • 14. Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment.
    Colleoni M, Viale G, Zahrieh D, Pruneri G, Gentilini O, Veronesi P, Gelber RD, Curigliano G, Torrisi R, Luini A, Intra M, Galimberti V, Renne G, Nolè F, Peruzzotti G, Goldhirsch A.
    Clin Cancer Res; 2004 Oct 01; 10(19):6622-8. PubMed ID: 15475452
    [Abstract] [Full Text] [Related]

  • 15. Prognostic significance of p53, bcl-2, and Bax expression in early breast cancer.
    Linjawi A, Kontogiannea M, Halwani F, Edwardes M, Meterissian S.
    J Am Coll Surg; 2004 Jan 01; 198(1):83-90. PubMed ID: 14698315
    [Abstract] [Full Text] [Related]

  • 16. p53 protein accumulation predicts resistance to endocrine therapy and decreased post-relapse survival in metastatic breast cancer.
    Yamashita H, Toyama T, Nishio M, Ando Y, Hamaguchi M, Zhang Z, Kobayashi S, Fujii Y, Iwase H.
    Breast Cancer Res; 2006 Jan 01; 8(4):R48. PubMed ID: 16869955
    [Abstract] [Full Text] [Related]

  • 17. Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer.
    Geisler S, Lønning PE, Aas T, Johnsen H, Fluge O, Haugen DF, Lillehaug JR, Akslen LA, Børresen-Dale AL.
    Cancer Res; 2001 Mar 15; 61(6):2505-12. PubMed ID: 11289122
    [Abstract] [Full Text] [Related]

  • 18. Vascular endothelial growth factor, p53, Rb, Bcl-2 expression and response to chemotherapy in advanced non-small cell lung cancer.
    Ludovini V, Gregorc V, Pistola L, Mihaylova Z, Floriani I, Darwish S, Stracci F, Tofanetti FR, Ferraldeschi M, Di Carlo L, Ragusa M, Daddi G, Tonato M.
    Lung Cancer; 2004 Oct 15; 46(1):77-85. PubMed ID: 15364135
    [Abstract] [Full Text] [Related]

  • 19. Bcl-2 protein expression is associated with p27 and p53 protein expressions and MIB-1 counts in breast cancer.
    Tsutsui S, Yasuda K, Suzuki K, Takeuchi H, Nishizaki T, Higashi H, Era S.
    BMC Cancer; 2006 Jul 13; 6():187. PubMed ID: 16839413
    [Abstract] [Full Text] [Related]

  • 20. p53 as a new prognostic factor for lymph node metastasis in penile carcinoma: analysis of 82 patients treated with amputation and bilateral lymphadenectomy.
    Lopes A, Bezerra AL, Pinto CA, Serrano SV, de MellO CA, Villa LL.
    J Urol; 2002 Jul 13; 168(1):81-6. PubMed ID: 12050497
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.